{"id":"am-lt","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Medecins Sans Frontieres, Netherlands","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":["Lariam®, Roche"],"company":"Medecins Sans Frontieres, Netherlands","patents":[],"pricing":[],"allNames":["am(lt)"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine am(lt) as a key that fits into a lock in the body. When it binds to the lock, it can either turn it on or off, or change the way it works. However, without knowing what the lock is or how it works, it's hard to understand exactly how am(lt) works its magic.","oneSentence":"am(lt) is a small molecule that works by interacting with a specific target in the body, but its exact mechanism is unknown.","technicalDetail":"As a small molecule, am(lt) likely works by binding to a specific protein or receptor in the body, altering its function or activity. However, the exact nature of this interaction and the resulting effects on the body are currently unknown."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=am%28lt%29","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=am(lt)","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:32:02.160981","biosimilars":[],"competitors":[],"genericName":"am(lt)","indications":{"approved":[{"name":"Epilepsy","diseaseId":"epilepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07462637","phase":"NA","title":"Signature Response to Light Therapy in Unipolar and Bipolar Major Depressive Episode (MDE)","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-03-01","conditions":["Major Depressive Episode"],"enrollment":173,"completionDate":"2029-05-01"},{"nctId":"NCT06604975","phase":"NA","title":"Arginin-stimulated Copeptin in Polyuria-polydipsia Syndrome in Children","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2025-03","conditions":["Primary Polydipsia","Central Diabetes Insipidus","Nephrogenic Diabetes Insipidus"],"enrollment":155,"completionDate":"2028-07"},{"nctId":"NCT02541695","phase":"NA","title":"Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli","status":"COMPLETED","sponsor":"NIZO Food Research","startDate":"2015-09","conditions":["Diarrhea","Gastroenteritis","Bacterial Infections","Escherichia Coli Infections"],"enrollment":44,"completionDate":"2017-01"},{"nctId":"NCT00313313","phase":"PHASE3","title":"A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":["Diabetes"],"enrollment":768,"completionDate":"2008-09"},{"nctId":"NCT00902811","phase":"PHASE4","title":"Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2008-12","conditions":["Uncomplicated Falciparum Malaria"],"enrollment":600,"completionDate":"2009-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Medecins Sans Frontieres, Netherlands","relationship":"Original Developer"}],"publicationCount":1618,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"originalDeveloper":"Medecins Sans Frontieres, Netherlands","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"AM(LT)","companyName":"Medecins Sans Frontieres, Netherlands","companyId":"medecins-sans-frontieres-netherlands","modality":"Small molecule","firstApprovalDate":"","aiSummary":"am(lt) is a small molecule drug developed by Medecins Sans Frontieres, Netherlands, but its target, drug class, and approved indications are unknown. As a small molecule, it is a type of chemical compound that can be used to treat various diseases. However, due to the lack of information, its commercial status, safety considerations, and mechanism of action are also unclear. Further research is needed to understand the properties and uses of am(lt).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}